Clinical trials: sponsored by Sun Yat-sen University
MAFLD
Liver Stiffness Changes by iLivTouch to Predict Liver-Related Events in MAFLD
This is an observational study (multicenter retrospective real-world cohort study). The purpose of this study is to assess the predictive performance of liver stiffness measurement (LSM, including baseline LSM1, current LSMC and…
- Trial name
- MAFLD (NCT07777198)
- Volunteers
- 2,303 people
- Sponsor
- Beijing Friendship Hospital
Bladder Cancer Stage IV
Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy
- Trial name
- NCT04562311
- Testing
- Chidamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer (Adenocarcinoma)
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery.
- Trial name
- NCT07907653
- Testing
- Deutenzalutamide, Docetaxel, ADT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Malignant Phyllodes Tumor of the Breast
Dynamic ctDNA Monitoring in Advanced Malignant Phyllodes Tumors of the Breast
Malignant phyllodes tumor of the breast is a rare fibroepithelial tumor. Patients with metastatic or unresectable disease have limited systemic treatment options, and there remains a need for biomarkers that can dynamically…
- Trial name
- NCT07903181
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a single-center, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of becotatug vedotin combined with gemcitabine and a PD-1 inhibitor as second-line or later treatment for patients with…
- Trial name
- NCT07902713
- Testing
- Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Non-Clear Cell Renal Cell Carcinoma (nccRCC)
A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma
People with non-clear cell renal cell carcinoma may remain at high risk of cancer recurrence even after surgery has removed all visible disease.
- Trial name
- SerF-ADJ (NCT07904156)
- Testing
- Serplulimab + Fruquintinib
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma, Immunotherapy
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
- Trial name
- RICE (NCT06510660)
- Testing
- adebrelimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Medical University Union Hospital
Nasopharyngeal Cancinoma (NPC)
Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy (Gemcitabine + Cisplatin) with Anlotinib plus Benmelstobart, followed by treatment allocation…
- Trial name
- RAPID (NCT07904819)
- Testing
- Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM)
- Volunteers
- 214 people
- Sponsor
- Sun Yat-sen University
Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)
Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical Trial
The goal of this clinical trial is to: a. To evaluate the safety and efficacy of sequential daratumumab followed by telitacicept in kidney transplant recipients with active/chronic active ABMR in participants aged 18-70 years…
- Trial name
- STABILIZE (NCT07902609)
- Testing
- Methylprednisolone (MP), Daratumumab, Telitacicept
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Systemic Health Risk
AI-Assisted Systemic Health Risk Assessment in General Ophthalmology
This study will evaluate whether providing ophthalmologists with additional artificial intelligence (AI)-assisted health risk information derived from routine retinal images affects subsequent clinical care in adults attending…
- Trial name
- LifeEye-RCT (NCT07890922)
- Testing
- AI-Assisted Health Risk Information
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Endometrial Cancer
A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer
This is a single-center, prospective, open-label, single-arm exploratory phase II study evaluating the efficacy and safety of cadonilimab combined with megestrol acetate as fertility-sparing treatment for patients with…
- Trial name
- NCT07900256
- Testing
- Cadonilimab, Megestrol Acetate (MA), Levonorgestrel-releasing intrauterine system
- Volunteers
- 10 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pulmonary Subsolid Nodules, Ground-Glass Nodules
Virtual Follow-up Prediction of Subsolid Pulmonary Nodules: A Prospective Silent Reader Study
The goal of this prospective, non-interventional study is to evaluate the predictive performance and potential clinical utility of an artificial intelligence (AI)-based virtual follow-up framework for incidentally detected…
- Trial name
- VF-PN (NCT07900815)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lymphoma, Large B-cell, Diffuse
30Gy Versus 40Gy Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy
The purpose of this study is to determine whether 30Gy radiotherapy is as effective as 40Gy in the treatment of localized Diffused Large B cell Lymphoma (DLBCL) when completing CR after chemotherapy.
- Trial name
- NCT01156259
- Testing
- Consolidative radiotherapy at 30 Gy, Consolidative radiotherapy at 40 Gy
- Where
- China
- Volunteers
- 432 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Radiation Induced Proctitis
Fecal Microbiota Transplantation for Radiation-Induced Proctopathy
The goal of this single-arm trial is to learn if Fecal Microbiota Transplantation (FMT) works to treat hemorrhagic radiation-induced proctopathy.
- Trial name
- NCT06776029
- Testing
- Fecal Microbiota Transplantation Capsule
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Adverse Drug Reaction, Cinepazide
Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study
Cinepazide Maleate Injection is widely used in cerebrovascular disease in china. The safety of the cinepazide, especially the blood system, has not been fully evaluated in Chinese population.
- Conditions
- Adverse Drug Reaction, Cinepazide, Stroke
- Trial name
- PACER (NCT01946919)
- Where
- 61 sites in China
- Volunteers
- 18,260 people
- Sponsor
- Peking University Third Hospital
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative)…
- Conditions
- Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
- Trial name
- NCT06144944
- Testing
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Upper Limb Volume Measurement
Clinical Trial of an Upper Limb Measurement Device
This clinical study evaluates an upper limb measurement device designed to measure upper limb volume. The study will compare measurements obtained using the upper limb measurement device with those obtained using the water…
- Trial name
- NCT07898410
- Testing
- Upper Limb Measurement Device
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepato Cellular Carcinoma (HCC)
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates…
- Trial name
- ACTION-001 (NCT07487662)
- Testing
- sintilimab, ipilimumab N01, Lenvatinib
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy with becotatug vedotin (MRG003) plus pucotenlimab, followed by treatment allocation based on…
- Trial name
- NCT07524413
- Testing
- Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy
- Volunteers
- 298 people
- Sponsor
- Sun Yat-sen University
Newly Diagnosed Glioblastoma, MGMT-Unmethylated Glioblastoma
A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated
The Primary Objective of this study is to evaluate the efficacy and safety of teniposide in combination with temozolomide for the treatment of newly diagnosed glioblastoma (nGBM) with MGMT promotor region unmethylated.
- Trial name
- NCT07894549
- Testing
- Teniposide Combined with Temozolomide
- Volunteers
- 72 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.